Logo image of EVOL

EVOLVING SYSTEMS INC (EVOL) Stock Fundamental Analysis

NASDAQ:EVOL - Nasdaq - US30049R2094 - Common Stock

1.08  -0.09 (-7.69%)

After market: 1.09 +0.01 (+0.93%)

Fundamental Rating

2

EVOL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 283 industry peers in the Software industry. EVOL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVOL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

EVOL had positive earnings in the past year.
EVOL Yearly Net Income VS EBIT VS OCF VS FCFEVOL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 5M -5M -10M

1.2 Ratios

Industry RankSector Rank
ROA 3.53%
ROE 6.96%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOL Yearly ROA, ROE, ROICEVOL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -20 -40 -60 -80 -100

1.3 Margins

Industry RankSector Rank
OM 4.6%
PM (TTM) 2.55%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVOL Yearly Profit, Operating, Gross MarginsEVOL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 -20 40 -40 60

5

2. Health

2.1 Basic Checks

EVOL has more shares outstanding than it did 1 year ago.
EVOL has a better debt/assets ratio than last year.
EVOL Yearly Shares OutstandingEVOL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2M 4M 6M 8M 10M
EVOL Yearly Total Debt VS Total AssetsEVOL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M 50M

2.2 Solvency

EVOL has an Altman-Z score of -2.71. This is a bad value and indicates that EVOL is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for EVOL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACCN/A
EVOL Yearly LT Debt VS Equity VS FCFEVOL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 10M 20M 30M

2.3 Liquidity

EVOL has a Current Ratio of 1.65. This is a normal value and indicates that EVOL is financially healthy and should not expect problems in meeting its short term obligations.
EVOL has a Quick Ratio of 1.65. This is a normal value and indicates that EVOL is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.65
EVOL Yearly Current Assets VS Current LiabilitesEVOL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M

2

3. Growth

3.1 Past

EVOL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.18%, which is quite impressive.
The earnings per share for EVOL have been decreasing by -12.39% on average. This is quite bad
The Revenue has been growing slightly by 5.06% in the past year.
EVOL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.59% yearly.
EPS 1Y (TTM)152.18%
EPS 3Y-15.48%
EPS 5Y-12.39%
EPS Q2Q%-46.42%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y-2.93%
Revenue growth 5Y0.59%
Sales Q2Q%3.01%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EVOL Yearly Revenue VS EstimatesEVOL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 10M 20M 30M
EVOL Yearly EPS VS EstimatesEVOL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 0.1 0.2 0.3 0.4 0.5

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.71, the valuation of EVOL can be described as very cheap.
When comparing the Price/Earnings ratio of EVOL to the average of the S&P500 Index (29.62), we can say EVOL is valued rather cheaply.
Industry RankSector Rank
PE 7.71
Fwd PE N/A
EVOL Price Earnings VS Forward Price EarningsEVOL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.75
EVOL Per share dataEVOL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

EVOL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

EVOLVING SYSTEMS INC

NASDAQ:EVOL (4/22/2022, 8:00:02 PM)

After market: 1.09 +0.01 (+0.93%)

1.08

-0.09 (-7.69%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)04-01 2022-04-01/amc
Earnings (Next)05-11 2022-05-11
Inst Owners2.74%
Inst Owner Change0%
Ins Owners19.24%
Ins Owner Change0%
Market Cap13.32M
Analysts82.86
Price TargetN/A
Short Float %0.02%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.71
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB N/A
EV/EBITDA 3.75
EPS(TTM)0.14
EY12.96%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.22
BVpS0.81
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.53%
ROE 6.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 4.6%
PM (TTM) 2.55%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover1.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.65
Altman-Z -2.71
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.18%
EPS 3Y-15.48%
EPS 5Y-12.39%
EPS Q2Q%-46.42%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.06%
Revenue growth 3Y-2.93%
Revenue growth 5Y0.59%
Sales Q2Q%3.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A